On May 23 & 24, Optimi will take the spotlight at the 4th Annual Psychedelic Therapeutics & Drug Development Conference in Boston. Bill will unveil his forward-thinking vision, titled “Manufacturing the Future of GMP Psychedelics,” before an audience of over 400 attendees, among them leading academics, clinical researchers, and practitioners from around the globe. A video of Bill’s presentation will be uploaded to our YouTube page within the next couple of weeks.

The 4th Annual Psychedelic Therapeutics and Drug Development Conference has been organized to bring together the world’s leading researchers and leaders in academia, industry, the non-profit sector and government to discuss the challenges and opportunities facing those engaged in the research and development of psychedelics for various health conditions with considerable unmet need. This event will highlight the progress being made towards regulatory approval of a variety of psychedelics with the potential to treat various conditions, including inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder.